Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Curaleaf HoldingsCURLF -1.18%72 Equity-to-Asset is 0.29 as of Mar. 2026, which is 37% below its 10-year median of 0.46. GuruFocus rates CURLF with a GF Score™ of 72/100 and a GF Value™ of $8.04 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 1,006 Drug Manufacturers companies, Curaleaf Holdings ranks worse than 83.9% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Curaleaf Holdings's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $821 Mil. Curaleaf Holdings's Total Assets for the quarter that ended in Mar. 2026 was $2,812 Mil.
Therefore, Curaleaf Holdings's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.29.
The historical rank and industry rank for Curaleaf Holdings's Equity-to-Asset or its related term are showing as below:
CURLF'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.27 Med: 0.46 Max: 1
Current: 0.29
During the past 12 years, the highest Equity to Asset Ratio of Curaleaf Holdings was 1.00. The lowest was -0.27. And the median was 0.46.
CURLF's Equity-to-Asset is ranked worse than 83.9% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs CURLF: 0.29
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Curaleaf Holdings Equity-to-Asset Related Terms
Curaleaf Holdings Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Curaleaf Holdings's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Curaleaf Holdings's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Curaleaf Holdings Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Curaleaf Holdings's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Curaleaf Holdings's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Curaleaf Holdings's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Curaleaf Holdings (CURLF) has a Equity-to-Asset of 0.29 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Curaleaf Holdings and its competitors. This is 37% below median its historical median of 0.46. According to the industry distribution chart, Curaleaf Holdings ranks #844 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 83.9%.
Is Curaleaf Holdings' Equity-to-Asset too high?
Curaleaf Holdings' current Equity-to-Asset of 0.29 is 37% below median its 10-year median of 0.46. The Drug Manufacturers industry median Equity-to-Asset is 0.61. Curaleaf Holdings' value of 0.29 is 52.5% below this industry median. Based on the distribution chart, Curaleaf Holdings ranks #844 out of 1006 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Curaleaf Holdings has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Curaleaf Holdings' Equity-to-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Curaleaf Holdings ranks #844 out of 1006 companies for Equity-to-Asset. This places Curaleaf Holdings in the lower half of its industry. The industry median Equity-to-Asset is 0.61. Curaleaf Holdings' value of 0.29 is 52.5% below this benchmark. While the company's 10-year median is 0.46 vs. the industry median of 0.61, Curaleaf Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Curaleaf Holdings's current Equity-to-Asset of 0.29 is 52.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Curaleaf Holdings and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Curaleaf Holdings's current Equity-to-Asset is 0.29, which is 37% below median its own 10-year median of 0.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curaleaf Holdings stock overvalued right now?
Based on GuruFocus' analysis, Curaleaf Holdings (CURLF) is currently considered Modestly Overvalued. The stock's GF Value™ is $8.04, compared to a current price of $9.24 — trading 14.9% above its estimated fair value. The current Equity-to-Asset is 0.29, which is 37% below median its 10-year median of 0.46 and 52.5% below the Drug Manufacturers industry median of 0.61. Curaleaf Holdings' overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Curaleaf Holdings (CURLF), the current Equity-to-Asset is 0.29 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Curaleaf Holdings (CURLF) Overvalued in 2026?
Based on GuruFocus' analysis, Curaleaf Holdings stock appears to be overvalued.
The current stock price of $9.24 is trading 14.9% above its estimated GF Value™ of $8.04.
GuruFocus considers Curaleaf Holdings to be Modestly Overvalued.
Key valuation signals for CURLF:
Equity-to-Asset: 0.29 (37% below median its 10-year median of 0.46)
GF Value™: $8.04 vs. price of $9.24 (14.9% above fair value)
Industry Position: 52.5% below the Drug Manufacturers median (#844 of 1006)
No single metric tells the full story. See the CURLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Curaleaf is headquartered in Wakefield, Massachusetts, and cultivates and sells medicinal and recreational cannabis in the US. The company has operations in 17 states. Its brands include Curaleaf, Select, and Grassroots. The company has made acquisitions that give it exposure to the growing European market, a unique feature among US multistate operators.
72GF Score
Get the complete analysis for CURLF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CURLF has been successfully added to your 
